Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) saw unusually-high trading volume on Wednesday . Approximately 153,157 shares changed hands during trading, an increase of 65% from the previous session’s volume of 92,946 shares.The stock last traded at $6.94 and had previously closed at $7.08.

Separately, Zacks Investment Research upgraded Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research note on Tuesday, July 12th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $15.94.

The company has a 50 day moving average price of $7.36 and a 200-day moving average price of $8.53. The firm’s market capitalization is $511.78 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/adaptimmune-therapeutics-plc-adap-sees-unusually-high-trading-volume.html

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last released its earnings results on Monday, August 8th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.16. On average, equities research analysts expect that Adaptimmune Therapeutics PLC – will post ($1.16) earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. New Leaf Venture Partners L.L.C. acquired a new position in Adaptimmune Therapeutics PLC – during the second quarter worth approximately $1,035,000. Adage Capital Partners GP L.L.C. boosted its position in Adaptimmune Therapeutics PLC – by 34.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,550,000 shares of the company’s stock worth $12,633,000 after buying an additional 400,000 shares in the last quarter. Glenmede Trust Co. NA boosted its position in Adaptimmune Therapeutics PLC – by 574.9% in the second quarter. Glenmede Trust Co. NA now owns 20,923 shares of the company’s stock worth $170,000 after buying an additional 17,823 shares in the last quarter. Rathbone Brothers plc boosted its position in Adaptimmune Therapeutics PLC – by 124.7% in the second quarter. Rathbone Brothers plc now owns 450,525 shares of the company’s stock worth $3,672,000 after buying an additional 250,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Adaptimmune Therapeutics PLC – by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock worth $888,000 after buying an additional 3,519 shares in the last quarter.

Adaptimmune Therapeutics PLC – Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

5 Day Chart for NASDAQ:ADAP

Receive News & Ratings for Adaptimmune Therapeutics PLC - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC - and related companies with MarketBeat.com's FREE daily email newsletter.